NDA 022037 · Takeda Pharms USA
Intuniv
Guanfacine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Dec 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Sep 2, 2009
Approved uses
5
Original approval plus efficacy supplements
Registered trials
85
15 Phase 3, 8 recruiting
FAERS reports
7,123
4,202 serious, 218 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2025.
INTUNIV ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14) ]. INTUNIV is a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications ( 1 , 14 ).
Mechanism: Guanfacine is a central alpha 2A -adrenergic receptor agonist. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 18, 2015 Supplement 11 · Efficacy Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Nov 19, 2014 Supplement 10 · Efficacy · priority review LabelPediatric Medical ReviewPediatric CDTL Review
- Feb 20, 2013 Supplement 8 · Efficacy LetterLabel
- Feb 25, 2011 Supplement 2 · Efficacy LabelLetter
- Sep 2, 2009 Original approval · Type 3 - New Dosage Form LabelReviewPediatric Medical Review
4 products under this application
- INTUNIV · GUANFACINE HYDROCHLORIDE EQ 3MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INTUNIV · GUANFACINE HYDROCHLORIDE EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INTUNIV · GUANFACINE HYDROCHLORIDE EQ 4MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- INTUNIV · GUANFACINE HYDROCHLORIDE EQ 2MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Guanfacine" as an intervention, any sponsor and status, largest first.
- DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00389779 · 849 participants · Start Sep 2006 · Primary completion Aug 2009
Drug: Darusentan; Guanfacine and 1 more · For: Hypertension
Sites: Birmingham, Alabama; Huntsville, Alabama; Montgomery, Alabama · 147 sites in all
- DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT00389675 · 661 participants · Start May 2007 · Primary completion Feb 2010
Drug: Darusentan; Guanfacine · For: Hypertension
Sites: Birmingham, Alabama; Huntsville, Alabama; Montgomery, Alabama · 99 sites in all
- Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT01081145 · 528 participants · Start May 11, 2010 · Primary completion Jun 3, 2013
Drug: Extended-release Guanfacine Hydrochloride · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; San Diego, California · 81 sites in all
- AWARE: Management of ADHD in Autism Spectrum DisorderPivotal-lookingRecruiting
Daniel CouryAcademic, hospital or other
NCT05916339 · 500 participants (planned) · Start Oct 1, 2023 · Primary completion Jan 1, 2027
Drug: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication; Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. · For: ADHD; Autism Spectrum Disorder
Sites: Irvine, California; Los Angeles, California; Portland, Maine · 13 sites in all
- Efficacy and Safety of SPD503 in Combination With PsychostimulantsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00734578 · 461 participants · Start Sep 2, 2008 · Primary completion Dec 10, 2009
Drug: SPD503-AM; SPD503-PM and 1 more · For: ADHD
Sites: Dothan, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 61 sites in all
- A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT04085172 · 396 participants · Start Sep 18, 2019 · Primary completion Sep 2, 2025
Drug: Guanfacine hydrochloride (TAK-503); Atomoxetine hydrochloride · For: Attention Deficit Hyperactivity Disorder
Sites: Dothan, Alabama; Anaheim, California; Imperial, California · 50 sites in all
- Treating Young Children With Attention Deficit Hyperactivity DisorderPivotal-lookingRecruiting
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT07300956 · 370 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 2030
Drug: Guanfacine (GUA); Methylphenidate (MPH) · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Palo Alto, California; Boston, Massachusetts; Kansas City, Missouri · 5 sites in all
- Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152009 · 345 participants · Start Jan 29, 2003 · Primary completion Aug 23, 2003
Drug: SPD503 (Guanfacine hydrochloride) (2 mg); SPD503 (3 mg) and 2 more · For: Attention Deficit Disorder With Hyperactivity
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective740
- off label use588
- somnolence433
- aggression362
- fatigue311
- hypotension277
- dizziness264
- headache255
- intentional overdose252
- suicidal ideation252
- insomnia250
- anxiety248
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 10 |
| 2010 | 101 |
| 2011 | 202 |
| 2012 | 178 |
| 2013 | 201 |
| 2014 | 315 |
| 2015 | 486 |
| 2016 | 457 |
| 2017 | 467 |
| 2018 | 468 |
| 2019 | 476 |
| 2020 | 473 |
| 2021 | 485 |
| 2022 | 537 |
| 2023 | 586 |
| 2024 | 604 |
| 2025 | 536 |
| 2026 | 532 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Intuniv (Guanfacine HCl)
2024 spending
$209K
Beneficiaries
69
426 claims
Per beneficiary
$3,026
$9.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $185,841 |
| 2021 | $203,202 |
| 2022 | $205,381 |
| 2023 | $228,107 |
| 2024 | $208,791 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, et al. · Lancet Psychiatry 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
Ostinelli EG, Schulze M, Zangani C, et al. · Lancet Psychiatry 2025 · Comparative Study, Network Meta-Analysis
- Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S, Çray O, Wu H, et al. · Mol Autism 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, et al. · PLoS One 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Radonjik NV, Bellato A, Khoury NM, et al. · CNS Drugs 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. · PLoS One 2017 · Systematic Review, Network Meta-Analysis
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.